Sodium Oxybate
Research News and Information

Tuesday, November 24, 2009

[Withdrawal syndrome after abuse of GHB (Gamma-Hydroxybutyrate) and its physiological precursors - its relevance for child and adolescent psychiatrists]

30 Aug 2009 BACKGROUND: The chronic abuse of Gamma-Hydroxybutyrate (GHB) as a designer drug as well as it's physiological precursors Gamma-Butyrolactone (GBL) and 1,4-Butandiole (1,4-BD) confronts child and adolescent psychiatrists with new challenges. The ... Read more...

1,4-Butanediol content of aqua dots children's craft toy beads.

30 Aug 2009 INTRODUCTION: The U.S. Consumer Product Safety Commission announced a recall of Aqua Dots (Spin Master Ltd.; Toronto, Canada) on November 7, 2007 due to children becoming ill after swallowing beads from these toy craft kits. Reports suggested that ... Read more...

Concentration-time profiles of gamma-hydroxybutyrate in blood after recreational doses are best described by zero-order rather than first-order kinetics.

29 Jun 2009 The recreational drug gamma-hydroxybutyrate (GHB) has a short plasma elimination half-life (t(1/2)) reported to be about 30-50 min. However, this represents a terminal half-life and therefore might not necessarily apply after large (abuse) doses are ... Read more...

Latest indexed articles for 'Sodium Oxybate'

These are the very latest articles for this heading:

• [Withdrawal syndrome after abuse of GHB (Gamma-Hydroxybutyrate) and its physiological precursors - its relevance for child and adolescent psychiatrists] 30 Aug 2009
• 1,4-Butanediol content of aqua dots children's craft toy beads. 30 Aug 2009
• Questioning the likelihood that sodium oxybate can be used to successfully treat fibromyalgia: comment on the article by Russell et al. 30 Aug 2009
• Concentration-time profiles of gamma-hydroxybutyrate in blood after recreational doses are best described by zero-order rather than first-order kinetics. 29 Jun 2009
• Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate. 29 Jun 2009
• Behavioral effects of gamma-hydroxybutyrate, its precursor gamma-butyrolactone, and GABA(B) receptor agonists: time course and differential antagonism by the GABA(B) receptor antagonist 3-aminopropyl(diethoxymethyl)phosphinic acid (CGP35348). 27 Jun 2009
• Pharmacological characterization of harmaline-induced tremor activity in mice. 31 May 2009
• Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. 31 May 2009
• Treatment of narcolepsy. 30 May 2009
• Sedative and hypothermic effects of gamma-hydroxybutyrate (GHB) in rats alone and in combination with other drugs: assessment using biotelemetry. 12 May 2009
• gamma-Hydroxybutyrate (GHB) induces GABA(B) receptor independent intracellular Ca2+ transients in astrocytes, but has no effect on GHB or GABA(B) receptors of medium spiny neurons in the nucleus accumbens. 11 May 2009
• Successful treatment of REM sleep behavior disorder with sodium oxybate. 29 Apr 2009
• [Severe delirium in withdrawal from chronic gamma-hydroxybutyric acid consumption] 29 Apr 2009
• Narcolepsy--master of disguise: evidence-based recommendations for management. 29 Apr 2009
• The drug of abuse gamma-hydroxybutyrate is a substrate for sodium-coupled monocarboxylate transporter (SMCT) 1 (SLC5A8): characterization of SMCT-mediated uptake and inhibition. 21 Apr 2009
• Metabolite profiling reveals YihU as a novel hydroxybutyrate dehydrogenase for alternative succinic semialdehyde metabolism in Escherichia coli. 14 Apr 2009
• Xyrem safety: the debate continues. 19 Mar 2009
• Three deaths associated with use of Xyrem. 7 Mar 2009
• Identification of GHB and morphine in hair in a case of drug-facilitated sexual assault. Mar 2009
• A patient with intractable posthypoxic myoclonus (Lance-Adams syndrome) treated with sodium oxybate. 27 Feb 2009

See a longer list of these articles.

Technical information about 'Sodium Oxybate'

Definition: The sodium salt of 4-hydroxybutyric acid. Anesthetic used for both induction and maintenance. It may cause bradycardia and dyskinesias.

Chemical name: Butanoic acid, 4-hydroxy-, monosodium salt

Registry Number: 502-85-2

Descriptor UI: D012978

Alternative terms: Sodium Oxybate; Oxybate, Sodium; Sodium Oxybutyrate; Oxybutyrate, Sodium; Sodium gamma-Hydroxybutyrate; Sodium gamma Hydroxybutyrate; 4-Hydroxybutyrate Sodium; 4 Hydroxybutyrate Sodium; Oxybate Sodium; Gamma-OH; Gamma OH; SERB Brand of Sodium Oxybate; Xyrem; Orphan Brand of Sodium Oxybate; gamma-Hydroxybutyrate; gamma Hydroxybutyrate; Somsanit; Köhler Brand of Sodium Oxybate;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Adjuvants, Anesthesia; Anesthetics, Intravenous;

Tree Number: D02.241.081.160.400.410.700; D02.241.511.400.410.700;

History Note: 91(75); was see under HYDROXYBUTYRATES 1975-90